09:45 AM EST - Resverlogix Corp. : Announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology. Resverlogix Corp.
shares T.RVX are trading unchanged at $1.77.
